News | July 17, 2009

PETNET to Supply SNM Multicenter Trial Network

July 17, 2009 – PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, announced today that it is a registered supplier of investigational 3’Deoxy-3’[18F] Fluorothymidine (F-18 FLT) to the Society of Nuclear Medicine’s Clinical Trial network.

This was made possible via a cross reference from Siemens Molecular Imaging/PETNET’s Drug Master File (DMF) to the SNM’s centralized IND.
 
This is in addition to the National Cancer Institute’s previous filing of a cross-reference letter to the same Type II Drug Master File that Siemens submitted to the U.S. Food and Drug Administration for its investigational 3’Deoxy-3’[18F] Fluorothymidine (F-18 FLT). The cross reference allows F-18 FLT to be produced and used by any principle investigator in an NCI or SNM multi-center clinical trial.
 
The imaging biomarker will also be available to investigators outside of the NCI and SNM trials, if they receive independent FDA approval of an IND or appropriate approval, such as a local Radioactive Drug Research Committee (RDRC) approval. F-18 FLT has been used in studies monitoring the proliferative activity of cancer cells and it is currently being used in clinical trials at several research sites. This cross reference to Siemens Molecular Imaging/PETNET’s DMF provides the medical community wider access to FLT by leveraging Siemens biomarker technology and the industry’s largest network of PET biomarker production facilities.

For more information: www.siemens.com/healthcare

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and pat
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...